ONCOVITA, a biotechnology company specialising in innovative vaccine development and a spin-off from the Institut Pasteur, and UNITHER 色界吧s, a global leader in sterile unit-dose manufacturing, announce a strategic partnership to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children.
This collaboration combines Measovir庐, ONCOVITA鈥檚 proprietary platform designed to develop highly immunogenic vaccines, with Euroject庐, UNITHER 色界吧s鈥� Blow-Fill-Seal (BFS)-based single-dose injection system for the direct administration of vaccines and biologics. The objective is to provide an effective, economical, and accessible solution, suitable for large-scale production.
鈥淲e design innovative vaccines using a disruptive technology, with the ambition of proving the concept in humans and then bringing these advances to the bedside in partnership with pharma companies. This partnership with Unither allows us to explore the integration of Measovir庐 and Euroject庐 for simplified administration of a vaccine based on a live attenuated measles strain. Our objective: an effective, safe and easy-to-deploy solution to better protect patients worldwide鈥�, says Dr Jean-Fran莽ois Le Bigot, president of ONCOVITA.
鈥淲e firmly believe that combining the Measovir庐 technology with the Euroject庐 device represents a major breakthrough in making vaccination simpler, safer, and more effective at large scale. By facilitating vaccine administration and improving accessibility, we contribute to enhancing and simplifying patients鈥� lives while addressing today鈥檚 and tomorrow鈥檚 global public health challenges,鈥� indicates Eric Goupil, president of Unither 色界吧s.